SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point of care ...
SAN DIEGO, Nov. 3, 2025 /PRNewswire/ -- The U.S. Food and Drug Administration ("FDA") has granted QuidelOrtho Corporation (QDEL) ("QuidelOrtho"), a global leader of in vitro diagnostics, 510(k) ...
QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid first-half 2024 performance and its continued ...
QuidelOrtho, a result of a 2022 business combination, was a strong player in the COVID-19 testing sector, generating $1.3 billion in 2021 from COVID products. The company experienced a dramatic drop ...
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care ...
Zacks Investment Research on MSN
Earnings preview: QuidelOrtho (QDEL) Q4 earnings expected to decline
Wall Street expects a year-over-year decline in earnings on lower revenues when QuidelOrtho (QDEL) reports results for the ...
SAN DIEGO, Aug. 21, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a global provider of innovative in-vitro diagnostic technologies designed for point-of ...
QuidelOrtho Corporation QDEL is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter 2024 results, is expected to ...
"We are pleased to successfully complete our debt refinancing, which allows us to strengthen our capital structure while maintaining financial flexibility," said Joseph Busky, Chief Financial Officer, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results